
uniQure (QURE) Stock Forecast & Price Target
uniQure (QURE) Analyst Ratings
Bulls say
uniQure NV reported revenues of $27.1M for 2024, marking a significant 71% year-over-year increase, largely attributed to $10M in license revenue from HEMGENIX royalties and $11M in collaboration revenue with Bristol Myers Squibb. The probability of success for its AMT-130 gene therapy has been raised to 75%, with expectations for a commercial launch in 2026, bolstered by promising FDA feedback and a supportive endpoint in clinical trials. Additionally, the risk-adjusted revenue estimates have increased to $1.8B, reflecting enhanced confidence in AMT-130's potential to become a breakthrough treatment for Huntington's disease.
Bears say
The financial outlook for uniQure NV appears negative due to decreased revenue estimates, with projections now suggesting annual peak revenues exceeding $2 billion may be difficult to achieve. Significant reductions in research and development expenses, resulting from a 65% workforce cut and facility sales, could impact the company's ability to advance its clinical pipeline effectively. Additionally, numerous risks, including potential delays in commercial launches and regulatory uncertainties, contribute to the speculative nature of uniQure's stock, indicating substantial volatility and uncertainties surrounding its future revenues.
This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares